Kyverna Therapeutics
KYTX | NASDAQ
$4.76
-$0.29 (-5.74%)
At close: Nov 16, 2026, 4:00 PM ET
$4.76
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 7:30 PM ET
-5.74%
(1D)No price chart data available for 1D timeframe.
Rating
26.8
Fundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #879/1021 (Top 86%)
Key Statistics
Market Data
Market Cap $300.94M
1D Range
4.74 5.05
52W Range
4.61 11.25
Valuation (TTM)
PE -1.72
PB 2.26
EV/EBITDA -1.06
Valuation (NTM)
Forward PE N/A
Forward PEG 0.07
Price Target $25.00
Cash Flow
FCF Yield -50.3%
SBC Adj. FCF Yield -54.6%
SBC Impact -8.6%
Margins
Gross Margin 0.0%
Operating Margin 0.0%
FCF Margin N/A
Growth (CAGR)
Revenue 3Y | 5Y N/A |
N/A
Dil EPS 3Y | 5Y -3.6% |
N/A
FCF 3Y | 5Y -19.7% |
N/A
Returns
ROA -83.3%
ROE -86.9%
ROIC -98.5%
Financial Health
Net Cash
$145.61M
Current Ratio 7.01
Interest Coverage -64.90
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous...
Sector Healthcare
Industry Biotechnology
Employees 149
IPO Date Feb 9, 2024
Website kyvernatx.com
Fiscal Year January - December
Latest News
No news articles available yet.
Analyst Summary
# of Analysts
4
Consensus
Buy
Price Target
$25.00
Upside
+425.21%
Buy (4)
Hold (0)
Sell (0)
Add to Watchlist
Select watchlists to add or remove KYTX